Company: CERO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001213900-25-010230
Chunk: 4

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 4
---
 were held by non-affiliates (without taking into account beneficial ownership or stock exchange limitations). If all of the 8,000,000 shares of Common Stock offered under this prospectus, including the 4,000,000 shares of Common Stock issuable upon exercise of the Pre-Funded Warrants and Offered Common Warrants, were issued and outstanding as of January 8, 2025 (without taking into account beneficial ownership or stock exchange limitations), such shares would represent approximately 65% of the total number of our fully-diluted shares of Common Stock outstanding and approximately 67% of the total number of our fully-diluted shares of Common Stock held by non-affiliates. You should read this prospectus and any prospectus supplement or amendment carefully before you invest in our securities. Our Common Stock is listed on Nasdaq under the symbol “CERO.” On February 3, 2025, the last quoted sale price for the shares of our Common Stock as reported on the Nasdaq was $2.00 per share. Our existing public warrants (the “Public Warrants”) are listed on Nasdaq under the symbol “CEROW,” and the last reported sale price of the Public Warrants on Nasdaq on February 3, 2025 was $0.014 per Public Warrant. The Offered Common Warrants do not have the same terms and conditions as our Public Warrants. The actual number of securities, and the combined offering price per share of Common Stock and the accompanying Offered Common Warrants, and the exercise price for the accompanying Offered Common Warrants will be as determined between us and investors at the time of pricing, and may be at a discount to the current market price of our Common Stock and the Public Warrants. Therefore, the recent market prices used throughout this prospectus may not be indicative of the actual public offering price of the shares of Common Stock and accompanying Offered Common Warrants. Currently, there is no public market for the Offered Common Warrants. We are an “emerging growth company” under applicable federal securities laws and are subject to reduced public company reporting requirements. We have engaged A.G.P./Alliance Global Partners (“A.G.P” or the “placement agent”) to act as our exclusive placement agent in connection with this offering. The placement agent has agreed to use its reasonable best efforts to arrange for the sale of the securities offered by this prospectus. The placement agent is not purchasing or selling any of the securities we are offering and